Diabetes Therapeutics Beyond Hyperglycaemia: Toward Biological Systems Redesign

Area of Science:

• Endocrinology and Metabolism
• Pharmacology
• Systems Biology

Background:

• Historically, diabetes treatment focused on glucose-centric models, primarily targeting blood glucose and HbA1c levels.
• While effective in managing diabetes as a chronic condition, this approach has limitations, evidenced by persistent cardiovascular, renal, inflammatory, and metabolic complications.

Purpose of the Study:

• To examine the conceptual transition in diabetes therapeutics beyond the traditional glucose-lowering paradigm.
• To propose a new unifying model for future diabetes treatment strategies.

Main Methods:

• Review of modern diabetes therapeutic advancements, including incretin-based therapies, organ-protective agents, immunological interventions, regenerative endocrinology, bioengineering, and AI-enabled systems.
• Analysis of how these advancements modulate interconnected physiological networks.

Main Results:

• Contemporary diabetes therapies increasingly derive efficacy from coordinated modulation of physiological networks, not just glucose reduction.
• Emerging treatments incorporate incretin-based therapies, organ protection, immunology, regenerative approaches, bioengineering, and AI.

Conclusions:

• The traditional glucose-centric model for diabetes is becoming insufficient.
• Biological systems redesign, focusing on integrated homeostasis, system resilience, and multi-scale disease interception, offers a unifying conceptual model for future diabetes therapeutics.